Comparison of Rimegepant and Placebo for Pain in IBS

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

NCT00945334 ·Status: COMPLETED ·Phase: NA

Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)

NCT05178017 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

NCT00399438 ·Status: COMPLETED ·Phase: PHASE2

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00731679 ·Status: COMPLETED ·Phase: PHASE3

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

NCT00607971 ·Status: TERMINATED ·Phase: PHASE3

Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)

NCT01149200 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

NCT02544152 ·Status: TERMINATED ·Phase: PHASE2

Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome

NCT00955994 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01887002 ·Status: TERMINATED ·Phase: PHASE2

Fecal Microbial Transplantation in Treatment of Irritable Bowel Syndrome; a Double Blinded Placebo Controlled Trial.

NCT02154867 ·Status: COMPLETED ·Phase: PHASE2

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

NCT02239926 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide

NCT00584298 ·Status: COMPLETED ·Phase: PHASE1

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455 ·Status: TERMINATED ·Phase: PHASE2

A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects

NCT02798991 ·Status: COMPLETED ·Phase: PHASE1

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00724126 ·Status: COMPLETED ·Phase: PHASE3

Brain Imaging and Pain in Irritable Bowel Syndrome

NCT00065754 ·Status: COMPLETED ·Phase: NA

Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain

NCT00441766 ·Status: TERMINATED ·Phase: PHASE2

To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

NCT05867550 ·Status: COMPLETED ·Phase: PHASE4

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

NCT04655599 ·Status: TERMINATED ·Phase: PHASE1

Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome

NCT00385099 ·Status: COMPLETED ·Phase: PHASE2

Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

NCT05482464 ·Status: COMPLETED ·Phase: NA

Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine

NCT00880594 ·Status: TERMINATED ·Phase: NA

A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679

NCT00511563 ·Status: WITHDRAWN ·Phase: PHASE2

Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid

NCT01449487 ·Status: COMPLETED ·Phase: PHASE1

Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome

NCT00108446 ·Status: COMPLETED ·Phase: PHASE2